Rapamycin + acarbose

2 papers3 findings

PubChem 5284616 PubChem 9811704 ChEBI 9168

C, W, M, H: cells, worms or flies, mice, humans. Dark: independent labs found the same change there. Light: one lab or one study. Outline: nothing yet.

Labs are independent when their papers share no last author and no institution.

Against: findings that point the other way from most findings on the same outcome.

On aging: the drug’s trials ARN judged to be about aging, of every trial that tests it for any use.

No results posted: trials that ended more than a year ago with no results on ClinicalTrials.gov and no paper in ARN’s record.

Company ties: findings with an author at a company, or from a paper whose competing-interests statement declares ties to one.

1 lab in 1 country
1 finding against

Funders: National Cancer Institute and 1 more

Animals2

Mouse lifespan

NIA ITP

Outcomes

Lifespan

upin mice2no changein mice1

2 studies

Rapamycin + acarbose increases lifespan in mice.
“rapamycin and acarbose have additive effects in delaying neurological symptoms and increasing maximum lifespan in Ndufs4-/- mice.”
Animalsin Ndufs4-/- mice
Acarbose suppresses symptoms of mitochondrial disease in a mouse model of Leigh syndrome
Nature metabolism26 Jun 2023
Rapamycin + acarbose has no effect on lifespan in mice.
“In females, lifespan in mice receiving both drugs was neither higher nor lower than that seen previously in Rapa only”
Animalsfemales
Lifespan benefits for the combination of rapamycin plus acarbose and for captopril in genetically heterogeneous mice
Aging cell30 Sep 2022
Rapamycin + acarbose extends lifespan in mice.
“In male mice, the combination of Rapa and Aca started at 9 months and led to a longer lifespan than in either of the two prior cohorts of mice treated with Rapa only”
Animalsmales
Lifespan benefits for the combination of rapamycin plus acarbose and for captopril in genetically heterogeneous mice
Aging cell30 Sep 2022